Abstracts Archive - Page 18 of 2607 - ACR Meeting Abstracts

Abstract Number: 0085 • ACR Convergence 2025
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Kensuke Suga¹, Amara Seng², Changfu Yao³, Tanyalak Parimon³, Youn Jung Choi², Justyna Fert-Bober⁴, Barry Stripp³, Jon Giles⁵, Peter Chen³ and Nunzio Bottini⁶, ¹Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…
Abstract Number: 0131 • ACR Convergence 2025
Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features
Kyla Rodgers¹, Cyrus Sarosh², Srilakshmi Yalavarthi³, Emily Becker⁴, Yiran Shen⁵, Kaitlyn Sabb⁴, Peter Hagan⁴, Ajay Tambralli⁵, Jacqueline Madison⁵, Yu (Ray) Zuo⁵ and Jason S. Knight⁵, ¹University of Michigan, Whitmore Lake, MI, ²University of Michigan, Temperance, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Libman-Sacks endocarditis (LSE) is an inflammatory phenomenon, typically involving the mitral or aortic valve, that affects some patients with systemic lupus erythematosus (SLE) and/or…
Abstract Number: 0124 • ACR Convergence 2025
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Haoyu Pan¹, Shiyan Gu¹, Xiaohan Wei², Yuying Fan¹, Jinyi Qian¹, Shuyi Yu¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
Abstract Number: 0207 • ACR Convergence 2025
The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
Suzi Hong¹, Marcos Monteon², Kathleen Bundy³, Chloe Delgado Ramirez³, Phoebe Senowitz³, Monica Guma⁴, Nina Acebo⁵, Chris Pruitt⁶, Tanya Shekhtman³, Shahrokh Golshan⁷ and Susan Lee⁸, ¹Herbert Wertheim School of Public Health and Human Longevity Science UCSD; Department of Psychiatry UCSD, San Diego, ²University of California, San Diego, San Diego, ³Department of Family Medicine, Center for Integrative Health, Krupp Endowment Fund, UCSD, La Jolla, ⁴University of California San Diego, San Diego, CA, ⁵University of California, San Diego, La Jolla, ⁶Herbert Wertheim School of Public Health and Human Longevity Science, UCSD, La Jolla, ⁷Department of Pyschiatry, UCSD, La Jolla, ⁸Department of Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: There have been over 777 million cases of acute COVID-19 infections worldwide as of April 2025. Although many patients recover, an estimated 10-30% of…
Abstract Number: 0144 • ACR Convergence 2025
Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
Zeynep Belce Erton¹, Joann Vega², Hannah Cohen³ and Doruk Erkan², ¹Hospital for Special Surgery, Brooklyn, NY, ²hospital for special surgery, New York, NY, ³University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: APS ACTION is a multidisciplinary, international research network focused on developing collaborative studies to improve antiphospholipid syndrome (APS) diagnosis and management. There is limited…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 0142 • ACR Convergence 2025
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Xiaohan Wei¹, Zhixia Yang², Haoyu Pan², Yuying Fan², Jinyi Qian², Shuyi Yu² and Hui Shi³, ¹Shanghai JiaoTong University, Shanghai, China (People's Republic), ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
Abstract Number: 0138 • ACR Convergence 2025
Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…
Abstract Number: 0165 • ACR Convergence 2025
Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
Nene Ukonu¹, David Felson², Michael LaValley³ and S. Reza Jafarzadeh⁴, ¹Boston University School of Public Health, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Anti-diabetic medications often have effects on other conditions. GLP1 agonists (GLP1a) have shown protective effects on OA outcomes in trials and short-term trial emulations,…
Abstract Number: 0172 • ACR Convergence 2025
Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review
Teresa Xiao¹, Namrata Singh² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Washington, Bellevue, WA, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: There is minimal guidance on specific cancer screening practices for rheumatic diseases (RDs) other than for myositis. The aim of this scoping review was…
Abstract Number: 0152 • ACR Convergence 2025
Exploring internet use and health information behaviour in patients with inflammatory rheumatic musculoskeletal diseases (RMD)
Ioana Andreica¹, Sulafa Chikh Mohamad², Dieter Wiek³, Birgit Barten³, Iulia Roman⁴, Anja Kremser⁵, David Kiefer⁶, Philipp Sewerin¹, Uta Kiltz⁷ and Xenofon Baraliakos⁷, ¹Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Germany, ³Deutsche Rheuma Liga, Germany, Bonn, ⁴Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Digital health literacy has recently become a focus of patient-centred recommendations, not only as a key social determinant of health, but also as a…
Abstract Number: 0182 • ACR Convergence 2025
A Joint Effort: Implementing Depression Screening in a Safety-Net Rheumatology Clinic
Clare Grossman¹, Jay Chhabra¹, Ximena Gonzalez Sanchez¹, Karina Brito¹, Jacqueline Friskey¹, Brent Abel² and Mary Margaretten², ¹University of California San Francisco, San Francisco, CA, ²Zuckerberg San Francisco General Hospital, UCSF, San Francisco, CA
Background/Purpose: Comorbid depression is common in patients with autoimmune diseases and is associated with increased healthcare utilization and death. Despite American College of Rheumatology recommendations…
Abstract Number: 0113 • ACR Convergence 2025
ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice
Shaghayegh Foroozan Boroojeni¹, Mansi Aparnathi², Akihiro Nakamura³, Zoya Qaiyum² and Nigil Haroon⁴, ¹University Health Network/University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory condition that primarily affects the musculoskeletal system and has multifactorial origins. The majority of AxSpA patients experience…
Abstract Number: 0084 • ACR Convergence 2025
Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
Keita Okamoto¹, Yasuto Araki², Yoshimi Aizaki², Hiroshi Kajiyama³, Kazuhiro Yokota², Yu Funakubo², Yuho Kadono⁴, Yuji Akiyama⁵ and Toshihide Mimura⁶, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-chou, Iruma-gun, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, ⁴Department of Orthopaedic Surgery, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, ⁵Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, ⁶Saitama Seikeikai Hospital, Higashimatsuyama, Saitama, Japan
Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASFs) produce various matrix metalloproteinases (MMPs), cytokines, and chemokines. Histone lysine methylation has been shown to play an important role…
Abstract Number: 2281 • ACR Convergence 2025
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Louis Bessette¹, Andrew Chow², Raman Rai³, Hugues Allard-Chamard⁴, Pauline Boulos⁵, Guylaine Roy⁶ and Dalinda Liazoghli⁶, ¹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ²Credit Valley Rheumatology, Mississauga, McMaster University, Hamilton, University of Toronto, Toronto, ON, Canada, ³Drs. Rai & Sekhon Medicine Professional Corporation, Brampton, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶AbbVie Corporation, Saint-Laurent, QC, Canada
Background/Purpose: Upadacitinib (UPA) is an oral, selective Janus kinase (JAK)-inhibitor proven effective and well-tolerated in patients with rheumatoid arthritis (RA) in 6 randomized clinical trials.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].